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Abstract
Background: Niemann-Pick type C (NPC) disease is a genetically inherited multi-lipid storage disorder with impaired efflux
of cholesterol from lysosomal storage organelles.
Methodology/Principal Findings: The effect of screen-selected cholesterol lowering compounds on the major sterol
pathways was studied in CT60 mutant CHO cells lacking NPC1 protein. Each of the selected chemicals decreases cholesterol
in the lysosomal storage organelles of NPC1 mutant cells through one or more of the following mechanisms: increased
cholesterol efflux from the cell, decreased uptake of low-density lipoproteins, and/or increased levels of cholesteryl esters.
Several chemicals promote efflux of cholesterol to extracellular acceptors in both non-NPC and NPC1 mutant cells. The
uptake of low-density lipoprotein-derived cholesterol is inhibited by some of the studied compounds.
Conclusions/Significance: Results herein provide the information for prioritized further studies in identifying molecular
targets of the chemicals. This approach proved successful in the identification of seven chemicals as novel inhibitors of
lysosomal acid lipase (Rosenbaum et al, Biochim. Biophys. Acta. 2009, 1791:1155–1165).
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Introduction
Niemann-Pick type C (NPC) disease is a fatal, neurodegenerative
disorder associated with an abnormal accumulation of unesterified
cholesterol and other lipids (such as sphingomyelin, bis-(mono-
acylglycerol)-phosphate, glycosphingolipids, and phospholipids) in
late endosome/lysosome (LE/LY)-like storage organelles (LSOs)
[1,2,3,4,5,6,7]. A defective gene responsible for most cases of NPC
disease was identified in 1997 as the NPC1 gene located on
chromosome 18q11 [8]. Later it was determined that about 5% of
NPC cases are caused by mutations in another gene, NPC2, located
on the chromosome 14q24.3 [9]. NPC1 protein is an integral
membrane protein associated primarily with late endosomes
[10,11,12]. NPC2 protein is a cholesterol-binding soluble protein
located within the lumen of the LE/LY [9,13]. The exact roles of
these two proteins in the movement of cholesterol out from the LE/
LY had not been deciphered [14,15,16,17,18,19].
Following the discovery of the link between NPC disease and
cholesterol [20], extensive studies were pursued on CHO cells
exhibiting an NPC phenotype and on human NPC mutant
fibroblasts [2,3,8,15,21,22,23]. This work led to better under-
standing of the changes in cholesterol transport and metabolism in
NPC-deficient cells.
Cholesterol (mostly esterified) is internalized into cells via
endocytosis of low-density lipoproteins (LDLs) taken up by the
LDL receptors and delivered to LE/LY, where hydrolysis of
cholesteryl esters by lysosomal acid lipase (LAL) takes place
[24,25]. In normal cells, the free cholesterol is then redistributed to
other organelles, such as the plasma membrane from which the
sterol can be effluxed to extracellular acceptors by ATP-binding
cassette transporters [26]. LDL-derived cholesterol is also
transported to the endoplasmic reticulum (ER), where esterifica-
tion of free cholesterol by acyl-coenzyme A:cholesterol acyltrans-
ferase (ACAT) [27] takes place. Cholesterol esters formed by
ACAT are stored as lipid droplets that are hydrolyzed by the
cytoplasmic neutral cholesterol ester hydrolase. Tightly regulated
cholesterol homeostatic mechanisms include de novo synthesis and
esterification of cholesterol as well as LDL receptor synthesis
[28,29].
In NPC mutant cells, the endocytic uptake of LDL and the
hydrolysis of LDL-derived cholesteryl esters to unesterified
cholesterol in LE/LY are normal. However, the rate of
cholesterol efflux from the LE/LY is severely impaired
[30,31,32], resulting in altered regulation of cholesterol homeo-
stasis [20,23,33]. Hence, despite the high levels of intracellular
cholesterol, the rates of the synthesis of both cholesterol and LDL
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by ACAT is diminished [20,31,32,34]. Additionally, the amount
of cholesterol transported from LE/LY to the plasma membrane
is reduced [35]. LE/LY with high levels of cholesterol and other
lipids such as bis-(monoacylglycerol)-phosphate contain multi-
layered internal whorls of membrane. Cholesterol in the LSOs
can be visualized by staining with filipin, a fluorescent polyene
antibiotic [36,37].
No fully effective treatment is available to date for NPC patients
[38]. Based on the current knowledge of NPC disease, potential
targets may mediate reduction of LE/LY lipid storage (cholesterol
and/or glycosphingolipids). In a search for chemical compounds
that could restore normal cholesterol distribution in NPC mutant
cells, an automated microscopy screen was developed to identify
compounds that partially correct cholesterol accumulation in
Chinese hamster ovary (CHO) NPC1-deficient cultured cells [39].
This automated assay quantifies sterol accumulation in the LSOs
based on images of the cells labeled with filipin. A good correlation
was found between the amount of cholesterol in the cells based on
the filipin staining and the amount of cellular cholesterol
determined by gas chromatography (GC) [39]. From an initial
screen of 14,956 combinatorially synthesized compounds, 14
compounds that reduced filipin staining of the LSOs at 10 mM
were identified. From a follow-up screen of an additional 3,962
compounds, seven compounds that are effective at lower
concentrations (123 nM to 3 mM) [39] were selected. Chemical
structures of these commercially available, screen-selected chem-
icals were published previously [39].
In the work presented herein the mechanisms by which screen-
selected sterol-lowering compounds reduce cholesterol levels in the
LSOs in cultured NPC1 CT60 cells were examined. The mutant
CT60 cells [40], with premature translational termination of the
NPC1 protein, are derived from 25RA, a CHO cell line with a
partial gain of function mutation in the SREBP (sterol regulatory
element binding protein) cleavage-activating protein (SCAP) [41].
The partial SCAP mutation of the CT60 cells exacerbates the
cholesterol-loading phenotype, a benefit in the analysis of
cholesterol transport and metabolism in NPC1 cells. Here, the
impact of the screen-selected compounds on cholesterol efflux to
extracellular acceptors, the uptake of lipoprotein-derived choles-
terol, and the amount of cholesteryl esters in compound-treated
cells was studied. We report that for each compound the decrease
in cholesterol level in the LSOs of the NPC1 mutant cultured cells
could be explained by at least one of the following: increased efflux
to extracellular acceptors, decreased uptake of lipoprotein-derived
cholesterol, or increased levels of cholesteryl esters. Analyzing the
general mechanisms of action through which the molecules reduce
sterol storage in the cells could help identify molecular targets of
the compounds. This approach has proven successful, since LAL
was determined as the target of several of the screen-selected
molecules [42]. We have included some of the previously
published results on the LAL inhibitors [42] herein to give the
reader the overall picture of the effects of the studied compounds
on the cholesterol transport and metabolism as inferred from the
biochemical analysis of the described pathways.
Materials and Methods
Materials
Chemical compounds were purchased from Chemical Diversity,
Inc. (San Diego, CA). Their chemical structures are provided in
the supplemental material (Figures S1 and S2) and also in [39].
Compound stocks of 10 mM in dimethyl sulfoxide (DMSO) were
stored at 220uC.
Cell medium Ham’s F12, fetal bovine serum (FBS), calf serum,
Hank’s balanced salt solution and Alexa Fluor 546 dye were all
obtained from Invitrogen Corporation (Carlsbad, CA). [1,2-
3H]-
cholesterol (51.2 Ci/mmol) and [1-
14C]-oleic acid (50 mCi/mmol)
were purchased from PerkinElmer Life Science (Boston, MA).
Solvents, bovine serum albumine (BSA) 99% fatty-acid, 4-(2-
hydroxyethyl)-1-piperazine ethane sulphonic acid (HEPES), fili-
pin, paraformaldehyde (PFA), mevinolin were all from Sigma
Chemicals (St. Louis, MO). Sodium DL-mevalonate was prepared
from DL-mevalonic acid lactone (Sigma Chemicals, MO)
according to published procedure [43].
MetaMorph image analysis software was from MDS Analytical
Technologies (Downington, PA).
Preparation of lipoprotein-deficient serum (LPDS) and
low-density lipoprotein (LDL)
LPDS was obtained from FBS adjusted to a final density of
1.2 g/ml [24]. LDL was obtained from human plasma, as
described in [24]. LDL was labeled with 1,19-dioctadecyl-
3,3,39,39-tetramethylindocarbocyanine perchlorate (DiI) (Invitro-
gen Corporation, Carlsbad, CA) as described elsewhere [44,45].
Cell lines
NPC1 mutant cell line CT60 and the parental cell line 25RA
were provided by Prof. T.Y. Chang (Dartmouth Medical School,
Hanover, NH).
Cells were grown in growth medium [Ham’s F12 medium, 1%
Penicillin/Streptomycin, 2 g/L glucose, 1.176 g/L sodium bicar-
bonate] supplemented with 10% FBS. Growth medium containing
5.5% FBS and 20 mM HEPES was designated medium A.
Evaluation of cholesteryl esters by GC
CT60 cells were plated in Falcon 12-well plates (VWR
International, Inc., Bridgeport, NJ) in growth medium with 10%
FBS, and after 24 h 10 mM of compound was added. The
procedure described in [39] was followed. The amount of
cholesteryl ester per mg protein was calculated for the solvent-
and compound-containing wells.
Incorporation of [
14C]-oleic acid into cholesteryl esters
CT60 cells plated in Falcon 24-wells were grown for 16–18 h in
medium A containing 10 mM chemical compound and 0.1 mM
[
14C]-oleate bound to albumin (prepared as described in [24]).
The procedure described in [42] was followed. The number of
pmoles of cholesteryl-[
14C]-oleate per mg protein was calculated
for each well.
Cholesterol efflux
Cells grown in Falcon 24-well plates in growth medium with
10% FBS were labeled with 1 mCi/ml [
3H]-cholesterol for 24 h.
The procedure described in [46] was followed. Efflux was
estimated as the radioactivity of the supernatant relative to the
sum of the radioactivity of supernatant and cell monolayer.
LDL uptake
Two different assays were used:
a. Short term uptake of DiI-LDL. CT60 cells were plated
in Costar 96-well black polystyrene flat, clear bottomed tissue
culture treated plates (Corning, Inc., NY) in growth medium
supplemented with 10% FBS. After 24 h incubation at 37uC,
medium was changed to one containing 5% LPDS. Following 16–
18 h incubation at 37uC, the plate was washed with phosphate
buffered saline (PBS) (pH 7.4) using a Bio-Tek Elx405 plate
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10 mM compound and 30 mg/ml DiI-LDL prepared in 5% LPDS-
medium was added to the cells. To the control samples, DMSO
was added (0.1% v/v) instead of the compound. Cells were
incubated for 35 min at 37uC and then washed with PBS, fixed
with 1.8% PFA for 10 min, and then stained with filipin (50 mg/
ml, 45 min). Images were acquired using Discovery-1 imaging
system from Molecular Devices (MDS Analytical Technologies)
equipped with a Xenon-arc lamp from Perkin Elmer (Waltham,
MA), a 10 X Plan Fluor 0.3 NA objective from Nikon (Melville,
NY) and a Photometrics CoolSnap HQ camera (139261040
pixels) from Roper Scientific (Tucson, AZ). For filipin, the
following filter set was used: [360 nm (40 nm bandpass)
excitation filter, 365 DCLP (DiChroic Long Pass) filter, 480 nm
(40 nm bandpass) emission filter], whereas for DiI, the filter set
was: [535 nm (40 nm bandpass) excitation filter, Chroma
51001 bs DiChroic filter, 610 nm (60 nm band pass) emission
filter]. Images were acquired at four sites per well using 262
binning. All images were corrected for background and shading
[39]. Cell area was determined based on the filipin images, and the
average DiI intensity per cell area was measured.
b. Long term uptake of DiI-LDL. Cells plated in Costar 96-
well plates were treated for 18 h with 10 mM compound and
6 mg/ml DiI-LDL in growth medium containing 10% FBA. The
assay described in [39] was followed. The average DiI intensity per
cell area was measured as described above.
Alpha 2-macroglobulin (a2M) uptake
CT60 cells were grown on poly-D-lysine-treated coverslip dishes
in growth medium with 10% FBS. After 48 h incubation at 37uC,
cells received medium A containing 100 mg/ml of receptor-
activated a2M [47,48] conjugated with Alexa Fluor 546 (a2M-
Alexa 546) and also 10 mM compound. After a pulse of 1 h at
37uC, cells were fixed with 1.8% PFA for 20 min at room
temperature. Cells were then washed with PBS, and then free
cholesterol was stained with filipin (50 mg/ml) for 90 min at room
temperature. Wide-field fluorescence images were acquired using
a Leica DMIRB microscope (Leica Mikroscopie und Systeme
GmbH, Wetzlar, Germany) equipped with a Princeton Instru-
ments cooled charged-coupled device camera (Princeton, NJ)
driven by MetaMorph System software. Images were acquired
with a high magnification oil immersion objective: 25x, 1.4 NA.
The following filter set was used to image filipin: [360 nm (40 nm
bandpass) excitation filter, 400 nm dichroic filter, and 470 nm
(40 nm bandpass) emission filter]. To minimize photobleaching, a
1.5% neutral density filter was utilized. To image Alexa 546 Fluor
a standard rhodamine filter set was used: [545 nm (30 nm
bandpass) excitation filter, 570 nm longpass dichroic filter, and
610 nm (75 nm bandpass) emission filter]. Once images were
corrected for background, cell area was determined based on the
filipin images, and then the average Alexa-546 intensity per cell
area was measured.
Inhibition of de novo synthesis of cholesterol
CT60 cells were plated in Costar 96-well plates (Corning, Inc.,
NY) in growth medium supplemented with 10% FBS. After 24 h
incubation at 37uC, cells were treated with medium A containing
mevinolin (20 mM) and mevalonate (230 mM) [49]. For control
cells only medium A was added. Following 18 h incubation at
37uC, cells were washed with PBS, fixed with 1.8% PFA for
10 min, and stained with filipin (50 mg/ml, 45 min). Images were
acquired using Discovery-1 (see above), and the analysis was
carried out using Metamorph Discovery-1 image-analysis software
and custom-designed analysis assays called the ‘‘filipin intensity
assay’’ and ‘‘LSO compartment ratio assay’’ which have been
described in detail [39]. Briefly, a low threshold was set to define
the area of the cells, and a high threshold was set to identify the
filipin-stained LSO regions. Filipin intensity assay describes the
total filipin intensity above the lower threshold divided by the
number of pixels above the lower threshold. The LSO
compartment ratio describes the total filipin intensity above the
high threshold divided by the cell area (mm
2) as defined by the low
threshold. Based on these two assays, cholesterol content in the cell
and in the LSOs, respectively was evaluated before and after
treatment with mevinolin/mevalonate.
Results
Cholesterol levels in the LSOs of NPC-deficient cells are very
high due to impaired efflux of the sterol from these organelles
[30,31,32]. With the use of a fluorescence automated microscopy
screen, small molecules that decrease cholesterol in the LSOs of
NPC1 mutant cultured cells were identified [39]. The cholesterol-
lowering effect of the screen-selected chemicals was validated upon
quantification by GC of the cellular cholesterol [39]. The
structures of the chemicals are presented in Supplemental material
(Figures S1 and S2). The majority of the chemicals did not exhibit
cytotoxic effects on NPC1 mutant cells treated for 24 h with
10 mM compound [39]. Based on cytotoxicity inferred from assays
measuring cell count and lactate dehydrogenase release [39],
compound 2a12 was eliminated from further studies. In addition,
compounds 1a2 and 2a3 were found to quench filipin fluorescence
by more than 20%. Hence, 1a2 and 2a3 were also eliminated from
further studies.
Here, the effect of the remaining 18 cholesterol-lowering,
screen-selected chemicals on intracellular cholesterol pathways
was studied. The effects of the compounds on cholesterol efflux
from cells, cholesterol uptake via lipoprotein endocytosis, and the
amount of cholesteryl esters in the cells were investigated. The
compounds did not show a uniform profile in terms of their
effects on these processes, indicating that their sterol-lowering
effects are based on several different mechanisms. Each
compound influenced one or more of these processes. Based on
the analysis of the pathways affected by seven of these cholesterol-
lowering small molecules (1a4, 1a11, 1a14, 2a8, 2a9, 2a13, 2a15),
an in depth study revealed that these chemicals are inhibitors of
LAL in CHO cells [42]. Moreover, we published data indicating
that compound 1a13 increased esterification by ACAT and
cholesterol efflux in both NPC mutant and normal cells [46].
Herein, we have retained the data on the LAL inhibitors (1a4,
1a11, 1a14, 2a8, 2a9, 2a13, 2a15) [42] and also on compound
1a13 [46] to give the reader an overall sense of all the processes
affected by each compound since only the effect of these
chemicals on specific processes was discussed in the previously
published work. Recognizing the cellular mechanisms impacted
by cholesterol-lowering chemicals could help reveal additional
molecular target(s) of these molecules, a difficult task associated
with any cell-based screening processes.
Evaluation of cholesteryl esters by GC in compound-
treated cells
The cholesteryl ester content of compound-treated and
untreated cells was quantified by extraction of cellular lipids,
saponification, and separation on a GC column (Figure 1). It can
be seen that the effects of the compounds on cholesteryl ester
content were variable. Seven compounds (1a4, 1a11, 1a14, 2a8,
2a9, 2a13 and 2a15) increased the cholesterol ester levels in the
cells to at least 150% of the control value [42]. The remaining
Compound Effects on NPC Cells
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significantly or decreased it.
Incorporation of [
14C]-oleic acid into cholesteryl esters
To further examine the effect of the compounds on cholesterol
esterification, the incorporation of [
14C]-oleic acid into cholesteryl-
[
14C] esters in cells treated with the selected compounds under the
screening conditions (18 hour incubation in FBS-containing
medium) was investigated. This assay analyzes whether the
compounds affect the transport of free cholesterol from the LSOs
to ACAT in the ER. As shown in Figure 2, only compound 1a13
increased ACAT esterification significantly after 18 h treatment of
the CT60 cells [46]. The increase in ACAT esterification shown
by compound 1a8 was not statistically significant, and all the other
16 compounds caused a decrease of [
14C]-oleic acid incorporation
into esters as compared to the control. The effect of compounds on
cholesterol esterification by ACAT was additionally tested by
treating the cells with [
14C]-cholesterol and quantifying [
14C]-
cholesteryl-oleate formed before and after addition of the chemical
to the cells. Once again, only compound 1a13 caused an increase
in the incorporation of cholesterol into esters, while all other
chemicals decreased esterification (not shown).
The seven compounds (1a4, 1a11, 1a14, 2a8, 2a9, 2a13 and
2a15) that did increase cholesteryl esters levels in the cells (Figure 1
and [42]) also inhibited hydrolysis of cholesteryl esters in LE/LY
[42]. However, these seven chemicals did not increase the ACAT
esterification (Figure 2 and [42]). A published study identified these
seven chemicals as novel inhibitors of LAL in the CHO cells [42].
The results described above show that except for the seven
chemicals identified as novel inhibitors of LAL in NPC-deficient
Figure 1. Quantification of cholesteryl ester levels by GC in CT60 cells treated with compounds. CT60 cells were treated with compound
(10 mM) overnight at 37uC and cellular lipids were extracted with hexane/isopropyl alcohol. Total cholesterol (after saponification) and free
cholesterol were measured, and the difference between these values was taken as the amount of cholesteryl ester. The amount of cholesteryl ester in
the cell per mg cell protein is reported (all values were referenced to the solvent-treated cells, to pool data from separate experiments for statistical
analysis purposes). For solvent-treated (control) CT60 cells, the mean value was 0.04260.004 mg cholesteryl ester/mg cell protein. Experimental values
for compound-treated cells were calculated as fraction of the control and are presented as mean 6 S.E. (*p,0.01). Two to four independent
experiments (6#n#12) were conducted. Data for compounds 1a4, 1a11, 1a14, 2a8, 2a9, 2a13 and 2a15 have been presented in [42].
doi:10.1371/journal.pone.0012788.g001
Figure 2. Incorporation of [
14C]-oleic acid into cholesteryl-[
14C] esters in CT60 cells treated with compounds. CT60 cells were plated in
growth medium with 10% FBS, at 37uC. After 24 h, the medium was changed to medium A containing10 mM compound and 0.1 mM [
14C]-oleate
bound to albumin. After 16–18 h at 37uC, cellular lipids were extracted with organic solvents and separated by thin layer chromatography. Data
analysis was performed using ImageQuant. The number of pmoles of cholesteryl-[
14C]-oleate per mg cell protein was calculated. For solvent-treated
(control) CT60 cells, the mean value was 1461. Experimental data of compound-treated cells were calculated as fractions of the control (to pool data
from separate experiments for statistical analysis purposes) and are presented as mean 6 S.E. (*p,0.01 and **p,0.02). Three to five independent
experiments (10#n#18) were conducted. Data for compounds 1a4, 1a11, 1a14, 2a8, 2a9, 2a13 and 2a15 have been presented in [42] and for 1a13 in
[46]. [14C]-CE: cholesteryl-[
14C]-ester.
doi:10.1371/journal.pone.0012788.g002
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driven esterification), the remaining chemicals did not affect
cholesterol esterification. Consequently, other cholesterol-related
cellular mechanisms were investigated to reveal the mechanisms
by which these molecules reduce cellular levels of cholesterol.
Since each chemical might affect more than one mechanism, the
studies described below included all 18 screen-selected chemicals.
Cholesterol efflux
The effect of the 18 compounds on cholesterol efflux to
extracellular acceptors was studied by incubating NPC1 mutant
CT60 cells with [
3H]-cholesterol for 24 h, followed by a chase for
16–18 h in the presence of compound (Figure 3A). Nine
compounds (1a1, 1a6, 1a10, 1a11, 1a13 [46], 1a14, 2a1, 2a13,
2a15) increased cholesterol efflux to at least 120% of the control
value. One compound (1a7) decreased cholesterol efflux. The
effect of the 18 compounds on cholesterol efflux was also
investigated in the parental, non-NPC cell line, 25RA
(Figure 3B). Interestingly, all nine compounds that increased
efflux in NPC1 mutant CT60 cells also increased cholesterol efflux
from parental 25RA cells (an increase to at least 150% of the
control value was observed – Figure 3B). The remaining
compounds affected the efflux in 25RA to a lesser extent or not
at all. Based on these cholesterol efflux studies, these nine
compounds (1a13 in particular [46]) could be considered valuable
candidates for promoting cholesterol efflux to extracellular
acceptors.
LDL and a2M uptake
The effect of the compounds on cholesterol uptake via
lipoprotein endocytosis was explored using DiI-LDL. A short-
pulse assay (35 min incubation with DiI-LDL) was designed to test
for chemicals’ direct effects on LDL endocytosis, whereas a long-
pulse assay (18 hours incubation with DiI-LDL) was a way to
check for secondary effects such as down regulation of the
expression of LDL receptor. The effect of 1a13 has been already
published [46], and experimental results indicated no direct effect
on LDL binding.
In the short-pulse assay (Figure 4A), five compounds (1a1, 1a3,
1a7, 1a8, 1a12) caused a moderate to strong decrease of LDL
Figure 3. Cholesterol efflux in the presence of compounds. Cells (CT60 or 25RA) were grown for 24 h in growth medium with 10% FBS, at
37uC and then labeled with 1 mCi/ml [
3H]-cholesterol for another 24 h at 37uC. Then cells were incubated for 2 h at 37uC in growth medium with 0.2%
BSA. Medium was replaced with medium A containing 10 mM compound. After 16–18 h chase at 37uC, the medium and cell monolayer were
collected. Efflux was expressed as the radioactivity of the supernatant relative to the sum of the radioactivity of supernatant and cell monolayer. The
mean value of the efflux of the control (DMSO-treated) cells was (6.960.3)% and (6.660.4)% for CT60 and 25RA cells, respectively. Experimental data
of compound-treated cells were calculated as fractions of the control (to pool data from separate experiments) and are presented as mean 6 S.E.
(*p,0.01). Two to six independent experiments (10#n#26) were conducted for CT60 cells, and two independent experiments (6#n#12) for 25RA
cells. Data for compound 1a13 have been presented in [46].
doi:10.1371/journal.pone.0012788.g003
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were grown in growth medium with 10% FBS for 24 h at 37uC, and then the medium was changed to 5% LPDS. After 16–18 h, 10 mM compound and
30 mg/ml DiI-LDL were added. Cells were incubated for 35 min at 37uC, fixed and stained with filipin. The average DiI intensity per cell area was
measured. Experimental data of compound-treated cells were calculated as fractions of the control (to pool data from separate experiments) and are
presented as mean 6 S.E. (*p,0.01). Four independent experiments (n=12) were conducted. (B) CT60 cells were grown on glass coverslip bottom
dishes. After 48 h incubation at 37uC, cells were incubated for 1 h in medium A containing 100 mg/ml of a2M-Alexa 546 and also 10 mM compound.
Cells were then fixed and stained with filipin. The average Alexa-546 intensity per cell area was measured. Experimental data of compound-treated
cells were calculated as fractions of the control and are presented as mean 6 S.E. (*p,0.01). Two to four independent experiments (10#n#19) were
conducted. (C) CT60 cells were plated in growth medium with 10% FBS, and after 24 h medium A with DiI-LDL (6 mg/ml) and 10 mM compound was
added. After 18 h at 37uC cells were fixed and stained with filipin. The average DiI intensity per cell area was measured. Experimental data of
compound-treated cells were calculated as fractions of the control and are presented as mean 6 S.E. (*p,0.01). Three independent experiments
(n=9) were conducted. Experimental results for compounds 2a1, 2a8, 2a9, 2a13, 2a15 have been published previously [39]. Data for compound 1a13
have been obtained using the procedure described in [46] and experimental results indicated no effect on LDL binding.
doi:10.1371/journal.pone.0012788.g004
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were 50–80% of the control value). The rest of the compounds
caused a smaller decrease in LDL uptake.
To check for general effects on endocytosis, the uptake of a2-
macroglobulin (a2M), a serum protease inhibitor, was also
examined for the five chemicals that caused the strongest effect
on the short-term uptake of DiI-LDL. The uptake of a2M is
mediated by the LDL receptor-related protein [47,48], one of the
seven members of the LDL receptor superfamily that is involved in
a variety of biological processes, including lipoprotein metabolism,
degradation of proteases and cellular entry of bacterial toxins and
viruses. Compounds that induced the strongest inhibition of LDL
uptake were tested for their effect on a 1 h uptake of a2M
conjugated with Alexa Fluor 546 (a2M-Alexa 546) (Figure 4B).
Compound 1a1 produced a small increase in a2M uptake, and
1a12 reduced a2M uptake, while the rest of the selected chemicals
did not affect a2M uptake, suggesting that they do not perturb
general endocytic processes in the cells.
The conditions for the 18 h LDL-uptake assay (Figure 4C)
followed closely the screening procedure used for the selection of
the compounds used in this study. It can be seen that all of the
compounds, except 2a15, caused inhibition of LDL internalization
during the 18 h treatment. Experimental results for the com-
pounds 2a1, 2a8, 2a9, 2a13, 2a15 have been reported previously
[39]. As indicated before, 1a13 also decreased uptake of LDL in an
18 hour assay [46]. The strong inhibition of LDL uptake upon
long incubation of the cells with several compounds may reflect
secondary effects such as down regulation of LDL receptor
expression. CT60 cells have only a partial gain of function
mutation in SCAP [40], which allows them to exhibit, at least to
some degree, cholesterol-regulatory homeostatic mechanisms.
Inhibition of the de novo synthesis of cholesterol
The effect of the inhibition of cholesterol biosynthesis on
cholesterol levels in CT60 cells was studied under experimental
conditions similar to those used for the screening assay. CT60 cells
were incubated for 18 h in the presence of both mevinolin (20 mM)
and mevalonate (230 mM) [49]. Since endogenous production of
mevalonate from acetyl-CoA is inhibited by mevinolin, small
amounts of mevalonate were added to the cell to allow production
of isoprenoids vital for the cell growth [50]. The effect of
mevinolin/mevalonate treatment on cholesterol level in the cells
was estimated using the two filipin-based assays previously
described [39]. In both assays, experimental results were
normalized to the average value of control cells that did not
receive mevinolin/mevalonate. Inhibition of cholesterol biosyn-
thesis did not affect the overall cholesterol levels in the cells, as no
effect was seen in the average filipin intensity assay (1.0060.01).
Furthermore, only a very small decrease of the cholesterol levels in
the LSOs was observed upon mevinolin/mevalonate treatment, as
indicated by the LSO filipin assay (0.9660.01, p=0.02).
Discussion
Chemical compounds studied in this work have been shown to
decrease overall cholesterol levels and cholesterol in the LSOs of
NPC1-deficient CHO cells [39]. The goal of this study was to
analyze which cholesterol transport processes and metabolic
pathways were affected by the compounds, as a first step in
identifying molecular targets of these compounds. Such informa-
tion can help to determine which chemicals could be of interest in
future investigations related to NPC or cholesterol metabolism in
general. The decrease of cholesterol in compound-treated NPC1-
deficient cells could be explained by one or more of the following:
increased efflux to extracellular acceptors, decreased uptake of
LDL-derived cholesterol, increased esterification of cholesterol or
decreased hydrolysis of cholesteryl esters. The latter two would
lead to increased levels of cholesteryl ester in cells. All these
possibilities were taken into consideration, and the effect of each
compound is summarized in Table 1. Experimental results showed
that each high throughput screen-selected chemical affects at least
one of the studied processes.
Compounds could act directly by promoting efflux from LSOs
or indirectly by reducing cholesterol levels elsewhere in the cell.
For example, inhibition of the uptake of LDL-derived cholesterol
and/or the decrease in the hydrolysis of cholesteryl esters could
lead to a reduction in the amount of free cholesterol produced in
the LE/LY. Since in the NPC-deficient cells the efflux of
cholesterol from the LE/LY is drastically diminished, a decline
in the rate of cholesterol production in these organelles might be
beneficial since there is evidence that sterol in the LSOs does
slowly exchange with other cellular sterol pools [51,52].
The selective inhibition of LDL uptake as compared to uptake
of a2M by some compounds suggests that they may be relatively
selective inhibitors of LDL uptake. After binding to the LDL
receptor-related protein, a2M enters cells by clathrin-dependent
receptor-mediated endocytosis and is delivered to lysosomes [53].
The internalized receptors (both the LDL receptor-related protein
and the LDL receptor) are recycled back to the cell surface.
Although the overall mechanisms of uptake of LDL receptor-
related protein and LDL receptor are very similar, some
differences have been reported. Interestingly, knockout of
autosomal recessive hypercholesterolemia, a clathrin adaptor
protein that interacts with both receptors, greatly decreases LDL
uptake with no effect on uptake of a2M by the LDL receptor-
related protein [54]. Further work would be required to determine
if interaction with autosomal recessive hypercholesterolemia
protein is related to the selective effects of some compounds on
LDL uptake.
Quantification by GC of the levels of cholesteryl ester in
compound-treated cells indicated that seven chemicals (1a4, 1a11,
1a14, 2a8, 2a9, 2a13 and 2a15) increased ester levels in the NPC1-
deficient CHO cells (Figure 1 and [42]). However, none of these
chemicals increased ACAT-driven esterification (Figure 2 and
[42]). An in depth study of the effects of these seven compounds
revealed that they inhibit LAL, the lysosomal enzyme that
hydrolyzes LDL-derived triacylglycerol and cholesteryl esters [42].
The assays used in this paper did not directly measure efflux of
sterol from the LSOs. However, it is expected that sterol released
from the LSOs would be available for either esterification by
ACAT, which resides in the ER, or efflux to extracellular
acceptors via the plasma membrane. Compound 1a13 was the
only compound that increased cholesterol efflux and increased
esterification by ACAT [46]. Moreover, in NPC1-deficient cells
treated with 1a13, the total cellular cholesterol was increased
slightly even as the filipin-labeled cholesterol in the LE/LY was
decreased [39]. All these results indicate that cholesterol delivered
via lipoproteins in the serum exits the LSOs upon treatment of the
NPC1 mutant cells with 1a13, and the sterol becomes available for
efflux to extracellular acceptors or esterification in the ER. These
experimental observations make 1a13 a candidate for directly
promoting sterol efflux from LSOs in NPC1-deficient and other
cells.
We also evaluated the possibility of decreasing cholesterol levels
in the cells through the inhibition of de novo synthesis of cholesterol.
CT60 cells were treated with mevalonin, which is an inhibitor of
hydroxymethylglutaryl CoA reductase (HMG-CoA reductase), the
rate limiting enzyme in the biosynthetic pathway of cholesterol. As
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small decrease in the sterol levels in the LSOs, as determined by
the filipin-based assay. Therefore, even if some of the chemicals
might have had inhibited HMG-CoA reductase and thereby
decreased de novo cholesterol synthesis, this metabolic process is
unlikely to be a key path to explain chemicals’ ability to lower
cholesterol accumulation in the LSOs in CT60 cells. Consistent
with this result, attempts to alleviate NPC symptoms through the
blockage of the endogeneous cholesterol synthesis have not been
successful [55].
Much remains to be unraveled from further studies of the 18
cholesterol-lowering compounds that partially revert the NPC
phenotype, as the molecular targets of only seven of the chemicals
have been identified [42]. Experimental results summarized in
Table 1 indicate that several compounds affect cholesterol efflux.
The active mechanism of the cholesterol efflux to extracellular
acceptors occurs via ATP binding cassette transporter A1
(ABCA1) and ATP binding cassette transporter G1 (ABCG1)
[56]. ABCA1 promotes efflux of cholesterol and phospholipids to
lipid-poor apolipoprotein A-1 or apolipoprotein E, while ABCG1
promotes efflux of cholesterol to high-density lipoprotein particles.
However, the details of the mechanisms underlying the ABCA1-
and ABCG1-mediated lipid efflux remain unclear. Nine chemicals
promoted cholesterol efflux in both non-NPC and NPC1-deficient
cells (1a1, 1a6, 1a10, 1a11, 1a13 [46], 1a14, 2a1, 2a13, 2a15). In
general the effect on efflux, relative to the control, in 25RA cells
was greater than in CT60 cells. One may correlate this
experimental observation to the fact that in CT60 cells there is
an impaired efflux of cholesterol from the LE/LY, compared to
25RA cells, so less cholesterol is available for transport to the
plasma membrane and extracellular acceptors. Among the nine
compounds indicated above, 1a10 and 1a11 induced the strongest
effect on efflux in 25RA cells. For each of these two chemicals the
relative increase in efflux in 25RA cells was over twice the level of
the effect seen in CT60 cells. Future studies may reveal whether
the impact on cholesterol efflux is a consequence of a direct effect
on the ABC transporters.
Alternatively, one may consider the possibility that the effects of
the chemicals on cholesterol efflux and/or the overall decrease of
the sterol in the cell are results of the activation of the nuclear liver
X receptor/retinoid X receptor (LXR/RXR). Oxysterols, inter-
mediates or end products in the metabolic pathway of cholesterol,
are endogenous LXR agonists and promote the induction of an
array of key proteins, among which are the efflux receptors
ABCA1 and ABCG1 [1,57]. Studies have shown that in NPC
mutant cells there is a defective ABCA1-dependent efflux [58] and
a diminished production of endogeneous oxysterol ligands for
LXR [59]. Published studies indicated that treatment with the
LXR agonist T0901317 of Npc1
2/2 mice prolonged their life
span, increased cholesterol excretion out of brain and improved
slightly the neurological function [60]. Future analysis may
indicate if any of the 18 sterol-lowering chemicals described
herein (which includes the nine compounds that affect cholesterol
efflux) are synthetic agonists of LXR or promote the formation of
natural LXR ligands.
Knowing the cholesterol pathways affected by the screen-
selected chemicals may help find relationships between chemicals’
structures and their molecular targets. For instance, compound
Table 1. Summary of the effects of screen-selected cholesterol-lowering compounds in CT60 cells.
Compound No.
Endocytosis of DiI-LDL.
Short term uptake assay.
Efflux to extracellular
acceptors.
Cholesteryl ester
levels. GC assay.
The most important effect(s) of the chemicals, to
explain cholesterol decreaseintheLSOsofCT60 cells.
1a6 Q
** qq
* -
1a9 Q
** q
* -
1a10 Q
* qq
* - increased efflux
1a13 - qqq
* -
2a1 Q
* qq
* -
1a4 Q
* q
** qqq
** increased levels of
2a8 Q
* - qqq
* cholesteryl ester
2a9 Q
* - qqq
**
1a11 Q
* qq
* qqq
*
1a14 Q
** qq
* qqq
** increased efflux and
2a13 Q
* qq
* qqq
* increased ester levels
2a15 Q
** qq
* qqq
*
1a3 QQ
* --
1a5 Q
* --
1a7 QQ
* Q
* - decreased LDL uptake
1a8 QQ
* q
* -
1a12 QQ
* q
* -
1a1 QQ
* qq
* qq
** increased efflux and ester levels, and decreased LDL uptake
Compounds were grouped based on their effect on key steps in cholesterol transport and metabolism that explain the decrease of the sterol in the LSOs in CT60 cells. A
compound is considered to affect a process if its effect meets the criterion of statistical relevance according to the student’s t-test;
*p,0.01 and
**p,0.1. Compound-triggered increased effect with respect to the control is indicated with an upward arrow (q), while a decrease is shown with a downward arrow
(Q). To distinguish between several compounds that affect the same process, a second criterion was used. A weak increase is considered one that induces a change
that is less than 20% and is indicated in the table by one arrow. A moderate change (20–50%) is shown by two arrows, whereas a strong increase corresponds to a
change of more than 50% and is shown with three arrows.
doi:10.1371/journal.pone.0012788.t001
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1a5, 1a6, 1a7 and 1a8. These compounds (except 1a7) increase
efflux in non-NPC 25RA cells by at least 20%. It is interesting to
note that 1a13 has a carboxyl group in the molecule, a group not
present in the other compounds.
The results presented in this manuscript emphasize advantages
of the biochemical analysis of the effects of screen-selected
compounds on key transport and metabolic processes as a crucial
step in the identification of molecular targets of the chemicals.
Since the specific pathway(s) related to LDL receptor-mediated
endocytosis affected by each compound have been identified, the
selection of compounds for further studies may be prioritized.
Synthesis of additional compounds, structurally derived from those
presented in this work, could lead to the discovery of chemically
more potent compounds, bearing structural features specific to
their in vivo binding partners.
Supporting Information
Figure S1 Chemical structures of the 14 cholesterol-lowering
chemicals screen-selected from a first library of compounds.
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Figure S2 Chemical structures of the seven cholesterol-lowering
chemicals screen-selected from a second library of compounds.
Found at: doi:10.1371/journal.pone.0012788.s002 (4.14 MB TIF)
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